Sign in

    Steven Wheen

    Research Analyst at Jarden

    Steven Wheen is the Head of Healthcare and Managing Director in Equity Research at Jarden, specializing in in-depth healthcare sector analysis. He covers a range of healthcare companies, leveraging his track record and experience from prior analyst roles at Evans & Partners, JP Morgan, and Macquarie Bank. Steve began his career after earning an Economics degree from the University of Sydney, bringing over a decade of research expertise before joining Jarden in April 2021. He is recognized for his analytical rigor and sector knowledge, holding leadership roles across leading financial institutions and providing advanced insights to institutional clients.

    Steven Wheen's questions to RESMED (RMD) leadership

    Steven Wheen's questions to RESMED (RMD) leadership • Q3 2025

    Question

    Steven Wheen of Jarden asked about the remaining runway for gross margin improvement above 60%, focusing on non-FX drivers like freight, manufacturing, and procurement.

    Answer

    CFO Brett Sandercock explained that the company is focused on building a sustainable, long-term pipeline of margin improvement initiatives. While significant progress has been made on freight optimization, further opportunities exist. He also cited manufacturing efficiencies from scale, platform maturity (AS10/AS11), and future design/procurement efforts as key drivers to continue expanding gross margin into the 60s.

    Ask Fintool Equity Research AI